Twitter | Search | |
Anders Perner
Professor, Intensive Care Rigshospitalet, UCPH. Chair Centre for Research in Intensive Care. Editor ICM. PI of , and trials.
1,603
Tweets
282
Following
1,761
Followers
Tweets
Anders Perner 10h
Vi kan desværre ikke være sikre på at det gavner patienterne da myndighederne godkender ny kræftmedicin uden at kræve at firmaerne har vist effekt på livskvalitet og overlevelse
Reply Retweet Like
Anders Perner 10h
Balanced view on the challenges we face in the implementation of AI AI brings opportunity and risk to the health sector
Reply Retweet Like
Anders Perner 10h
Obviously but adjustments represent a more conservative approach. EMA in general may be less conservative eg. allowing surrogate outcomes thereby approving drugs on a less certain basis
Reply Retweet Like
Anders Perner Jul 20
Det gælder alle behandlinger, men vi har et problem. Vi har ikke etableret et system hvor vi systematisk tester behandlinger. Derfor baserer kun 10% af alle behandlinger på god evidens. 10%!!! Patientnær forskning bør prioriteres
Reply Retweet Like
Anders Perner Jul 20
If so they should be prioritised. A hierarchical analysis could be an alternative. Still if there are more outcomes within a 'family', p-value adjustment should be done. A theme for ?
Reply Retweet Like
Anders Perner Jul 20
Replying to @timothygirard
Difficult but I would think that family-wise error rate may be used so that they are not totally independent. Some punishment for many outcomes appear rational to avoid cherry picking
Reply Retweet Like
Anders Perner Jul 20
Very important progress in medical science 'the notion that a treatment is effective for a particular outcome if P<0.05 and ineffective if that threshold is not reached is a reductionist view of medicine that does not always reflect reality.'
Reply Retweet Like
Anders Perner Jul 20
Reply Retweet Like
Anders Perner retweeted
Vinay Prasad Jul 17
There are so many things wrong with this article. Sadly it is just more HYPE that misleads the public about the issues
Reply Retweet Like
Anders Perner retweeted
JAMA Jul 16
The Bleeding Edge, a 2018 Netflix documentary, tells stories of patient harm from medical device failures to urge reform of a system designed to facilitate approval and diffusion of technologies ahead of clear evidence of safety
Reply Retweet Like
Anders Perner Jul 16
On the climate crisis of medicine (but it's a general theme) from 'Why must we allow the stock market, rather than clinicians and public health systems, to decide which new lifesaving medicines are developed and made available to patients?'
Reply Retweet Like
Anders Perner Jul 15
Replying to @LarsIgum
Det man forhåbentligt kan sige uden at træde nogen over tæerne er... Der bør gennemføres et godt klinisk forsøg med laveste mulige risiko for systematisk fejl for at effekt på det det betyder noget for patienterne.
Reply Retweet Like
Anders Perner Jul 14
Replying to @LasseTKrogsbll
Og efterlader mange patienter uden testede behandlinger og mange behandlinger uden sikker viden om gavn og mulig skade
Reply Retweet Like
Anders Perner Jul 13
Vi har ikke et system hvor behandlinger kan testes hurtigt og omkostningseffektivt. Cannabis er kun en af mange behandlinger som gives uden god evidens - kun 10% er baseret god evidens 😨 Et nationalt center for kliniske forsøg vil forbedre behandlingen for 1000-vis af patienter
Reply Retweet Like
Anders Perner retweeted
Intensive Care Society Jul 13
State of the Art 2019: 9-11th December. Have you booked yet? Programme coming very soon but in the meantime, check out... 😎The speakers page 👊Opportunities to present your work 🕺💃Social events 👋 Networking opportunities Tomorrow's Care, Today
Reply Retweet Like
Anders Perner retweeted
The BMJ Jul 12
More than half of new drugs in Germany lack proof of added benefit over existing treatments. The current state of affairs suggests a policy failure. We need new approaches, says this
Reply Retweet Like
Anders Perner Jul 12
Likely to be important to have a central produce for research-fraud investigations for the worst cases. Process control of methodology much more important to improve basic, translational and epidemiological research in particular. Look at RCTs methodology
Reply Retweet Like
Anders Perner Jul 11
Reply Retweet Like
Anders Perner Jul 11
No worries. I think we repeat our successes. The 6S and TRISS trials have improved fluid and transfusion therapy in and saved the lives of thousands of patients
Reply Retweet Like
Anders Perner Jul 11
Replying to @WSHT_ICU
We have changed to protocol trying to recruit patients earlier in their course and restricting all IV fluids
Reply Retweet Like